AI, Robotics and Biotech Funding Activity in August 2026
A roundup of major financing rounds across artificial intelligence, robotics and biotechnology reported in August 2026.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
Sophiie AI, an Australian startup building an AI operating system for trades, raised A$5 million in a seed round at a A$30 million valuation. Investors included Archangel Ventures, Admiralty Capital Group, Antler, Gandel Invest and Aussie Angels. The capital will fund a new platform version, team expansion and entry into the United States after already serving thousands of businesses in Australia, New Zealand and the UK [3].
Harell Data Corp., founded by former Adaptive Biotechnologies co‑founder Harlan Robins, closed a $15 million seed round from Fuse, Cercano Management and other backers. The platform lets data owners host proprietary datasets in a secure environment where AI developers can train models without extracting the raw data, and it shares compute‑revenue directly with the owners. Initial partners include Adaptive Biotechnologies and A‑Alpha Bio, and the company aims to expand the model beyond computational medicine [1].
Robotics
Neura Robotics of Metzingen, Germany, announced a plan to raise up to €1 billion (approximately $1.2 billion) to launch production of a humanoid robot capable of heavy‑object handling and repetitive‑task automation. The fundraising aims to attract investors to support the company’s entry into the competitive humanoid market alongside firms such as Tesla and 1X Technologies, building on a €120 million round earlier in 2025 that included Lingotto Investment Management, Volvo Cars Tech Fund and others [4].
Genetic Engineering
Abcuro, an autoimmune‑disease biotech, completed a $66 million Series D on 18 August 2026 with investors including New Leaf Venture Partners, Bain Capital Life Sciences, Sanofi Ventures, NEA and others. The funds will support a new clinical study of its monoclonal antibody ulviprubart in patients with less severe inclusion body myositis, following a phase 2/3 trial that showed a positive signal in a pre‑specified subgroup [2].
Leal Therapeutics raised an additional $30 million in a Series A extension that added Eli Lilly as a new investor alongside existing backers such as OrbiMed, Euclidean Capital and Chugai Venture Fund. The capital will advance its oral glutaminase inhibitor LTX‑001 in schizophrenia through a Phase 1b/2a trial and move LTX‑002 further in a Phase ½ ALS study, while also supporting pre‑clinical pipeline development [5].